Treatment of Osteoporosis With Vitamin D

Buring, Klas; Huith, A. G.; Nilsson, Bo; Westlin, Nils E.; Wiklund, P. E.

doi:10.1111/j.0954-6820.1974.tb08173.x

Cited by 13 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the first groups to explore this approach was that of Buring et al [140]. In the 1970s, the awareness that intestinal calcium absorption declined with age and the possibility that it was lower in osteoporotic subjects than other elderly individuals, led to an interest in using pharmacological doses of vitamin D (the only available vitamin D preparation at that time) to increase intestinal calcium absorption.…”

Section: Pharmacological Usementioning

confidence: 99%

“…It is difficult to assess the safety of pharmacological doses of vitamin D from the published series because some contain small numbers of patients [140] and others made no comment on the subject of side effects [141,142]. However, there are sufficient case reports of severe hypercalcemia, often of long duration and sometimes associated with renal failure, to counsel great caution in the use of these regimens [162,163].…”

Section: Safetymentioning

confidence: 99%

See 1 more Smart Citation

Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis

Bouillon

Reid

2013

Osteoporosis

View full text Add to dashboard Cite

Section: Pharmacological Usementioning

confidence: 99%

Section: Safetymentioning

confidence: 99%

Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis

Bouillon

Reid

2013

Osteoporosis

View full text Add to dashboard Cite

Osteoarthrosis, spinal degenerative disease and other back pain syndromes

Liyanage¹

1986

Therapeutics in Rheumatology

View full text Add to dashboard Cite

Early Postmenopausal Bone Loss is Prevented by Estrogen and Partially by 1α-OH-vitamin D3: Therapeutic Effects of Estrogen and/or 1α-OH-vitamin D3

et al. 1999

View full text Add to dashboard Cite

A total of 79 Japanese women who were within 5 years of menopause were randomly assigned 1alpha-hydroxyvitamin D3 [1alpha(OH)D3] 1.0 microg/day, conjugated estrogens 0.625 mg/day, a combination of both, or control (no treatment). Lumbar spine and proximal femur bone mineral density (BMD) and biochemical indices were monitored over 2 years. In the 1alpha(OH)D3-treated group, there was a nonsignificant decrease in lumbar spine BMD compared with controls, and no significant loss in the femoral neck compared with controls. In the estrogen-treated group, there was a nonsignificant increase in spine BMD (+2.17% in the first year and +1.71% in the second year), and no loss in femoral neck BMD. The combination of conjugated estrogens +1alpha(OH)D3 was more effective in increasing BMD in the spine (+3. 68% in the first year and +3.63% in the second year) and femur (+2. 56% in the first year and +4.44% in the second year) BMD. There was a significant difference in lumbar spine BMD in both the first and second years between the combination-treated group and the 1alpha(OH)D3-treated and control groups (P < 0.01). Serum osteocalcin (OC) significantly decreased in the combination-treated group (-23.8% in the first year) and the estrogen-treated group (-37. 6% and -41.2% at 6 and 18 months, respectively), and serum alkaline phosphatase (Alp) decreased significantly in the first year in the combination-treated (-31.5%), estrogen-treated (-27.3%), and 1alpha(OH)D3-treated (-7.9%) groups, whereas serum OC increased (+45. 4% in the first year) in women without treatment. The results of this study indicate that early postmenopausal bone loss in the femoral neck is prevented by conjugated estrogens, 1alpha(OH)D3, or both, whereas bone loss in the spine is not prevented by 1alpha(OH)D3. Estrogen proves effective in preventing early postmenopausal bone loss by markedly inhibiting bone turnover. Moreover, a synergistic bone-sparing effect can be expected when estrogen is administered concomitantly with 1alpha(OH)D3 rather than when used alone.

show abstract

Treatment of Osteoporosis With Vitamin D

Abstract: Abstract. A daily intake of 35000 IU vitamin D2 and calcium supplement for one year could not be demonstrated to influence the bone mineral mass in the forearm of 23 women with osteoporosis.

Cited by 13 publications

References 7 publications

Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis

Vitamin D and its Metabolites and Analogs in the Management of Osteoporosis

Osteoarthrosis, spinal degenerative disease and other back pain syndromes

Early Postmenopausal Bone Loss is Prevented by Estrogen and Partially by 1α-OH-vitamin D3: Therapeutic Effects of Estrogen and/or 1α-OH-vitamin D3

Contact Info

Product

Resources

About